Clinical Trial Update: Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ibrutinib plus nab-paclitaxel and gemcitabine in first-line metastatic pancreatic adenocarcinoma completed with posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Ibrutinib (ibrutinib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2020-11-16